Doxorubicin Resistance in B16 Melanoma Cells
Author Information
Author(s): R. Supino, M. Mariani, G. Capranico, A. Colombo, G. Parmiani
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
Can acquired resistance of B16 melanoma cells to doxorubicin be associated with altered membrane transport and differences in drug-induced DNA breakage?
Conclusion
The study found that doxorubicin resistance in B16 melanoma cells is linked to lower drug uptake and retention, as well as biochemical changes affecting drug action.
Supporting Evidence
- Resistant B16 cells showed lower doxorubicin uptake compared to sensitive cells.
- Drug efflux was higher in resistant cells than in sensitive cells.
- DNA breaks induced by doxorubicin were fewer in resistant cells at the same drug concentration.
Takeaway
This study shows that some cancer cells can become resistant to a drug called doxorubicin, making it harder for the drug to work. This happens because the cells don't take in the drug as well and also change how they handle it inside.
Methodology
The study involved comparing drug uptake and DNA breakage in sensitive and resistant B16 melanoma cell lines after exposure to doxorubicin.
Limitations
The study may not fully account for all factors affecting drug resistance in vivo, such as tumor vascularization and drug metabolism.
Want to read the original?
Access the complete publication on the publisher's website